SecBot SecBot
8-K ·Filed Aug 14, 2026

OTLK

Outlook Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed3mo ago SEC0001104659-26-096510
Actionable Insight ▼ Bearish

The stock will likely trade down toward the $0.99 offering price as the market absorbs the new shares. Watch for the stock to settle below the $1.10 warrant exercise price, which would render the warrants worthless and reduce overhang. The 60-day lock-up expires in mid-October, setting up a potential secondary selling event. Participation by insiders (CEO, CFO, largest stockholder) is a modest positive signal but does not offset the dilution.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.7564
T+0 close · Aug 14, 2026 · via day close
Latest settled
−39.28%
T+60 · $0.4593
Vs SPY
−36.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $0.7564entry
  2. T+1 · 3mo ago −11.13%α −10.66% · $0.6722
  3. T+5 · 3mo ago −14.44%α −13.07% · $0.6472
  4. T+20 · 2mo ago −15.67%α −13.67% · $0.6379
  5. T+60 · 8d ago −39.28%α −36.23% · $0.4593
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Outlook Therapeutics priced a $55.0M registered direct offering of 55,555,556 shares of common stock and accompanying warrants to purchase up to 55,555,556 shares, at a combined price of $0.99 per unit. The underwriters also exercised their option to purchase additional warrants covering 8,333,333 shares. The offering is heavily dilutive (~33% of current market cap in base shares alone) and the warrants, exercisable at $1.10 for 5 years, create additional overhang. The company's largest stockholder, CEO, and CFO participated, signaling some insider confidence, but the dilutive structure and low offering price relative to the $166M market cap are clearly negative for existing holders.

Key Facts

  • 55,555,556 shares + 55,555,556 warrants sold at $0.99/unit ($0.98 per share + $0.01 per warrant)
  • Gross proceeds of approximately $55.0 million before expenses and underwriting discounts
  • Underwriters' option for 8,333,333 additional shares/warrants was exercised for warrants only
  • Warrants have a $1.10 exercise price, 5-year term, exercisable immediately
  • Purchase price to underwriters: $0.9306 per unit ($0.9212 per share + $0.0094 per warrant)
  • GMS Ventures (largest stockholder) bought 2,525,252 units; CEO Robert Jahr bought 151,515 units; CFO Lawrence Kenyon bought 101,010 units
  • Closing scheduled for August 14, 2026; 60-day lock-up for directors, officers, and certain stockholders
  • Underwriters include Piper Sandler & Co., BTIG, LLC, and Brookline Capital Markets

Financial Impact

~$55.0M gross proceeds with immediate 33%+ dilution from base offering; additional ~$9.2M if warrants exercised (at $1.10 strike); 5-year warrant overhang of up to 63,888,889 shares

dilutionshare countcash runway

Risk Factors

  • Massive dilution: 55.6M new shares versus pre-offering float (market cap $166M / $0.99 = ~168M shares pre-offering, so ~33% dilution from base offering alone)
  • Warrant overhang: up to 63.9M additional shares exercisable at $1.10, which may cap upside near that level
  • Stock may trade below the $0.99 offering price post-close as new investors look to exit
  • Biotech cash-burn risk: if runway doesn't extend to a catalyst, further dilution likely

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (OTLK), Batch item 10001104659-26-096510
Document: tm2622399d2_ex4-1.htm0001104659-26-096510
Document: tm2622399d2_8k.htm0001104659-26-096510
Document: tm2622399d2_ex5-1.htm0001104659-26-096510
Document: 0001104659-26-096510-index-headers.html0001104659-26-096510
Document: 0001104659-26-096510-index.html0001104659-26-096510
Document: 0001104659-26-096510.txt0001104659-26-096510
8-K Filing (OTLK), Batch item 80001104659-26-096510

Track record

37 reports on OTLK

Performance horizon

12 of 22 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 17 of 22 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Viewing Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026